Section Arrow
TBPH.NASDAQ
- Theravance Biopharma
Quotes are at least 15-min delayed:2026/01/09 06:56 EST
Pre Market
Last
 18.97
-0.05 (-0.26%)
Bid
7.61
Ask
22.42
High 18.97 
Low 18.97 
Volume
Regular Hours (Closed)
Last
 19.02
+0.14 (+0.74%)
Day High 
19.06 
Prev. Close
18.88 
1-M High
19.25 
Volume 
291.00K 
Bid
7.61
Ask
22.42
Day Low
18.53 
Open
18.71 
1-M Low
17.25 
Market Cap 
956.70M 
Currency 美元 
P/E 33.12 
%Yield -- 
10-SMA 18.62 
20-SMA 18.32 
50-SMA 17.6 
52-W High 20.33 
52-W Low 7.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.57/-0.11
Enterprise Value
995.80M
Balance Sheet
Book Value Per Share
4.59
Cash Flow
Cash Flow Yield
0.26
Income Statement
Total Revenue
64.38M
Operating Revenue Per Share
1.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1033-0.0223-17.75%-- 
Pre Market 0.1034 +0.0001 +0.10%
ACRVAcrivon Therapeutics1.93-1.02-34.58%-- 
Pre Market 1.83 -0.1 -5.18%
VTYXVentyx Biosciences13.84+0.11+0.80%-- 
Pre Market 13.83 -0.01 -0.07%
MLTXMoonLake Immunotherapeutics14.34+3.05+27.02%-- 
Pre Market 14.65 +0.31 +2.16%
CRMDCorMedix7.51-3.66-32.77%5.05PE
Pre Market 7.6 +0.09 +1.20%
Industry overview quotes are at least 15 minutes delayed
Business Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.